Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $114.86 USD
Change Today +0.11 / 0.10%
Volume 2.9M
CELG On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
NASDAQ GM
As of 3:02 PM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

86 Morris Avenue

Summit, NJ 07901

United States

Phone: 908-673-9000

Fax:

se-modifying outcomes for serious diseases that lack adequate therapy. The company has developed proprietary technology for collecting, processing, and storing placental stem cells with therapeutic applications in cancer, auto-immune diseases, and other inflammatory diseases. The company is developing its cellular therapies, PDA-001 (IV formulation) and PDA-002 (IM/SC injectable formulation), with the initiation of a PDA-001 phase I safety and dose finding study for Crohn’s disease and a PDA-002 phase II study in peripheral arterial diseases. The company is also continuing research to define the potential of placental-derived stem cells and to characterize other placental-derived products. CC-486: The company has initiated two phase III trials of CC-486 that are enrolling to evaluate CC-486 in the treatment of MDS and acute myeloid leukemia. In addition, a phase I trial of CC-486 for the treatment of solid tumors is in progress. Sotatercept (ACE-011) and luspatercept (ACE-536): The company has collaborated with Acceleron Pharma, Inc. to develop sotatercept and luspatercept to treat anemia in patients with rare blood disorders. Various phase II trials are in progress to evaluate the use of sotatercept or luspatercept in the treatment of anemia in patients with rare blood disorders and chronic kidney disease, beta-thalassemia, and MDS. mTOR Pathway Inhibitors: CC-223 and CC-115 target the important cancer pathway that is dysregulated in a large proportion of cancers. In particular, activity is being investigated in lymphomas, hepatocellular, and prostate cancers in phase I/II trials. Epigenetics: The insights into molecular regulation of genetic information (Epigenetics) have the potential to transform human diseases. Celgene has two epigenetic modifiers on the market, VIDAZA and ISTODAX. In addition, the company is collaborating with Epizyme Inc. to develop EPZ-5676 for acute myeloid leukemia. International Operations The company conducts its international operations in approximately 50 countries and has sales in approximately 70 countries and regions, including Europe, Latin America, the Middle East, the Asia/Pacific, and Canada. Distribution In various countries, the company promotes its products through its own sales organizations. In some countries, particularly in Latin America, it partners with third-party distributors. The company distributes its products through commonly used channels in local markets. However, REVLIMID, POMALYST/IMNOVID, and THALOMID/Thalidomide Celgene are distributed under mandatory risk-management distribution programs tailored to meet local authorities' specifications to provide for their safe and appropriate distribution and use. Research and Development The company’s research and development expenses amounted to $2.431 billion in 2014. Patents and Proprietary Technology As of December 31, 2014, the company owned or had exclusively licensed 591 issued U.S. patents and 596 additional pending U.S. patent applications. Patent term extensions have been granted in other markets, as well for certain of the company’s patents related to REVLIMID. Patent term extensions for certain of its patents related to lenalidomide have been granted in Australia, Korea, Japan, and Russia. Further, patent term extensions for certain of the company’s patents related to ABRAXANE have been secured and/or are being sought in Australia, Japan, Russia, and Korea. The company is also considering alternative exclusivity strategies, primarily through international treaties, in various countries throughout Latin America. Governmental Regulation The company is subject to regulation under the Occupational Safety and Health Act; the Toxic Substances Control Act; the Resource Conservation and Recovery Act; and other federal, state, and local laws, rules and regulations. Competition The company’s competitors include major pharmaceutical and biotechnology companies, and specialty pharmaceutical firms, including but not limited to: Hematology and Oncology: Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanof

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CELG:US $114.88 USD +0.13

CELG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $63.41 USD -0.13
Biogen Inc $421.91 USD -1.01
Bristol-Myers Squibb Co $66.72 USD +0.86
Medtronic PLC $77.13 USD -0.01
Shire PLC 5,575 GBp +90.00
View Industry Companies
 

Industry Analysis

CELG

Industry Average

Valuation CELG Industry Range
Price/Earnings 47.4x
Price/Sales 11.8x
Price/Book 13.9x
Price/Cash Flow 40.2x
TEV/Sales 10.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.